Abstracts tagged "radiography"

Abstract Number: 0493 • ACR Convergence 2020
Automatic Joint Space Assessment in Hand Radiographs with Deep Learning Among Patients with Rheumatoid Arthritis
Yun-Ju Huang¹, Chang-Fu Kuo¹, Fakai Wang², Shun Miao², Kang Zheng² and Le Lu², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), ²PAII labs, Bethesda, MD
Background/Purpose: Assessment of joint space is the fundamental radiographic task to diagnose rheumatoid arthritis (RA) and to assess the severity and progression of the disease.…
Abstract Number: 0727 • ACR Convergence 2020
Hip Involvement Leads to Poor Outcome in Adulthood in Children with Enthesitis Related Arthritis (ERA) Category of Juvenile Idiopathic Arthritis (JIA)
Naveen R¹, Namita Mohindra¹, Neeraj Jain¹ and Amita Aggarwal², ¹Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Enthesitis related arthritis (ERA) is the commonest category of JIA seen in India and constitutes 30-40% of all JIA patients. There are many studies…
Abstract Number: 0748 • ACR Convergence 2020
Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis
Andreas Kerschbaumer¹, Gabriela Supp², Farideh Alasti¹, Josef Smolen² and Daniel Aletaha¹, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized through symmetric polyarthritis leading to joint destruction over time in many patients. Radiographic damage is…
Abstract Number: 0754 • ACR Convergence 2020
The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs
Takayoshi Owada¹, Ayae Tanaka², Hirokuni Hirata¹, Masafumi Arima³, Yasutsugu Fukushima¹ and Kazuhiro Kurasawa³, ¹Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan, ²Dokkyo Medical University, Shimotsuga-Gun, Japan, ³Dokkyo Medical University, Mibu, Shimotsugagun, Tochigi, Japan
Background/Purpose: Rheumatoid factors (RFs) are RA-related autoantibodies like anti-cyclic citrullinated peptide antibodies, and are used for classifying and diagnosing RA. In addition, positivity and high…
Abstract Number: 1049 • ACR Convergence 2020
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
Paul Dellaripa¹, Martin Aringer², Anna Maria Hoffmann-Vold³, Clive Kelly⁴, Shikha Mittoo⁵, Alexandra James⁶, Klaus Rohr⁶, Susanne Stowasser⁶ and Yoshikazu Inoue⁷, ¹Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle upon Tyne, United Kingdom, ⁵University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁷Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan, Sakai City, Osaka, Japan
Background/Purpose: In the INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in patients with…
Abstract Number: 1161 • ACR Convergence 2020
Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis
Farzana Nuruzzaman¹, Mingqian Huang², Christian Hedrich³, Hermann Girschick⁴, Julie Cherian⁵, T. Shawn Sato⁶, Karen Onel⁷, Polly Ferguson⁸ and Yongdong Zhao⁹, ¹Stony Brook Children's Hospital, Stony Brook, NY, ²Mount Sinai Hospital, 10003, NY, ³University of Liverpool, Liverpool, United Kingdom, ⁴Vivantes Children’s Hospital, Wuerzburg, Germany, ⁵Stony Brook Children�s Hospital, Stony Brook, NY, ⁶University of Iowa, Iowa City, ⁷Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁸University of Iowa Carver College of Medicine, Iowa City, IA, ⁹University of Washington, Seattle, WA
Background/Purpose: Radiological imaging is integral to the diagnosis of chronic nonbacterial osteomyelitis (CNO) and has been included as a central component in suggested diagnostic criteria…
Abstract Number: 1235 • ACR Convergence 2020
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND
Désirée van der Heijde¹, Cynthia E Kartman², Li Xie², Scott Beattie², Douglas Schlichting², Patrick Durez³, Yoshiya Tanaka⁴ and Roy Fleischmann⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Eli Lilly and Company, Indianapolis, IN, ³Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Baricitinib (BARI) is an oral, reversible and selective Janus kinase 1 and 2 inhibitor. Treatment with once-daily oral BARI resulted in low rates of…
Abstract Number: 1458 • ACR Convergence 2020
Slower Current Walking Speed Is Associated with Progression in Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project
Lindsey Duca¹, Liubov Arbeeva², Yvonne Golightly³, Louise Murphy⁴, Charles Helmick⁴ and Kamil Barbour⁵, ¹Centers for Disease Control and Prevention, Chamblee, GA, ²University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ³University of North Carolina at Chapel Hill Dept of Epidemiology, Chapel Hill, NC, ⁴Centers for Disease Control and Prevention, Atlanta, GA, ⁵CDC, Atlanta, GA
Background/Purpose: Poorer physical functioning as a single baseline measurement has been associated with increased risk of radiographic knee osteoarthritis (rKOA) progression, but it is unknown…
Abstract Number: 1487 • ACR Convergence 2020
Biclustering Reveals Potential Knee Osteoarthritis Phenotypes in Exploratory Analyses: Data from the Osteoarthritis Initiative
Amanda Nelson¹, Thomas Keefe², Todd Schwartz³, Richard Loeser¹, Yvonne Golightly⁴, Liubov Arbeeva¹ and J Marron², ¹University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina at Chapel Hill Dept of Biostatistics, Chapel Hill, NC, ⁴University of North Carolina at Chapel Hill Dept of Epidemiology, Chapel Hill, NC
Background/Purpose: To utilize novel methodologies to explore subgroups within the OAI clinical data.Methods: From the OAI baseline dataset (n=4796 individuals with or at risk of…
Abstract Number: 1644 • ACR Convergence 2020
Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis
Ali Guermazi¹, Frank Roemer², Andrew Kompel¹, Luis Diaz³, Michel Crema⁴, Mark Brown⁵, Anne Hickman⁵, Glenn Pixton⁶, Lars Viktrup⁷, Robert Fountaine⁵, Aimee Burr⁵, Sarah Sherlock⁵ and Christine West⁸, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Boston Veteran Affairs Healthcare System, Boston, MA, ⁴Boston University School of Medicine, Paris, France, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc., Morrisville, NC, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tanezumab is a nerve growth factor monoclonal antibody in development for osteoarthritis (OA). Following a clinical hold due to concerns around adverse joint events,…
Abstract Number: 568 • 2019 ACR/ARP Annual Meeting
Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility
Farhan Syed¹, Kassel Fotinos-Hoyer ², Michael O'Connor ³, Maureen Li ³, Bryan Hermannsson ², Nicholas Enus ³, Sayali Karve ³, Manish Sharma ⁴, Gabriele Pradella ³, Robert B.M. Landewé ⁵, Xenofon Baraliakos ⁶ and Sarah Warner ³, ¹Parexel, Billerica, MA, ²Parexel, Berlin, Germany, ³Parexel, Billerica, ⁴Parexel, Hyderabad, India, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ⁶Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is typically radiographically confirmed on the sacroiliac joint (SIJ) as assessed by the modified New York (mNY) criteria. In clinical trials,…
Abstract Number: 618 • 2019 ACR/ARP Annual Meeting
Factors Associated with Complete Spinal Fusion in Patients with Ankylosing Spondylitis
Yasmin Maldonado¹, Michael Weisman ², Lianne Gensler ³, Michael Ward ⁴, Matthew Brown ⁵, MinJae Lee ⁶, Mark Hwang ⁶, Mariko Ishimori ⁷, Amirali Tahanan ⁶, Tom Learch ⁷, Mohammad Rahbar ⁶ and John Reveille ⁸, ¹The University of Texas-McGovern Medical School, Houston, TX, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³University San Francisco California, San Francisco, CA, ⁴NIAMS, Bethesda, MD, ⁵Queensland University of Technology, Queensland, Australia, ⁶University of Texas-McGovern Medical School, Houston, TX, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸University of Texas McGovern Medical School, Houston
Background/Purpose: Most patients with ankylosing spondylitis (AS) do not develop complete spinal fusion. The purpose of this study was to compare patients with complete spinal…
Abstract Number: 938 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity
Alexandre Sepriano¹, Sofia Ramiro ², Stephanie Wichuk ³, Praveena Chiowchanwisawakit ⁴, Terrie MacCosham ³, Joel Paschke ⁵, Désirée van der Heijde ¹, Robert B.M. Landewé ⁶ and Walter Maksymowych ⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³University of Alberta, Edmonton, Canada, ⁴Mahidol University, Bangkok, Thailand, ⁵CARE Arthritis, Edmonton, Canada, ⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ⁷University of Alberta and CARE Arthritis, Edmonton, Canada
Background/Purpose: Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the…
Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting
Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study
Philip Mease¹, Robert B.M. Landewé ², Proton Rahman ³, Hasan Tahir ⁴, Atul Singhal ⁵, Elke Böttcher ⁶, Sandra Navarra ⁷, Aimee Readie ⁸, Shephard Mpofu ⁹, Evie Maria Delicha ⁹, Luminita Pricop ⁸ and Désirée van der Heijde ¹⁰, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Southwest Rheumatology, Dallas, TX, ⁶Rheumazentrum Favoriten, Vienna, Austria, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…
Abstract Number: 2185 • 2019 ACR/ARP Annual Meeting
MRI-detected Abnormalities in Prediction Models of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up
C. Kent Kwoh¹, Frank Roemer ², Erin Ashbeck ³, ChengCheng Hu ¹, Edward Bedrick ¹, Leena Sharma ⁴ and Ali Guermazi ⁵, ¹University of Arizona, Tucson, AZ, ²University of Erlangen-Nuremberg, Erlangen, Germany, ³The University of Arizona Arthritis Center, University of Arizona, Tuccson, AZ, Tucson, AL, ⁴Northwestern University, Chicago, IL, ⁵Boston Medical Center, Boston
Background/Purpose: MRI Osteoarthritis Knee Score (MOAKS) is a semi-quantitative scoring system used to assess MRI-detected structural abnormalities including over 100 raw scores representing multiple joint…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].